Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
54 hedge funds and large institutions have $86.3M invested in Clearside Biomedical in 2017 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 16 reducing their positions, and 6 closing their positions.
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
8% more funds holding
Funds holding: 50 → 54 (+4)
0.2% less ownership
Funds ownership: 3.44% → 3.24% (-0.2%)
6% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 16
24% less capital invested
Capital invested by funds: $114M → $86.3M (-$27.8M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.07M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$813K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$372K |
| 4 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$316K |
| 5 |
TI
Trexquant Investment
Stamford,
Connecticut
|
+$257K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.2M |
| 2 |
BlackRock
New York
|
-$2.69M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.32M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$658K |
| 5 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$533K |
CLSD Hedge Fund Activity: Q4 2017 in Review
54 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q4 2017, worth a combined $86.3M — down 24% from $114M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CLSD positions and 6 closed out — a net gain of 4 holders — while 15 added to existing stakes and 16 trimmed.
The largest buyer was Sphera Funds Management, adding an estimated $1.07M. The largest seller was Fidelity Investments, cutting an estimated $3.2M.
- 54 institutional investors held Clearside Biomedical (CLSD) as of Q4 2017, up from 50 in Q3 2017.
- Funds reported $86.3M of Clearside Biomedical stock for Q4 2017, down 24% quarter-over-quarter.
- 10 funds opened new Clearside Biomedical positions in Q4 2017 and 6 closed out, a net change of +4 holders.
- The largest Clearside Biomedical buyer in Q4 2017 was Sphera Funds Management, an estimated $1.07M added.
- The largest Clearside Biomedical seller in Q4 2017 was Fidelity Investments, an estimated $3.2M sold.
Based on aggregated 13F filings for Q4 2017.